Freenome
Freenome is a biotechnology company specializing in early cancer detection using a multiomics platform, focusing on blood-based tests for colorectal and lung cancers.
Services
Freenome focuses on early cancer detection through its multiomics technology platform. The company provides a blood-based test for the early detection of colorectal cancer. This test aims to identify cancerous changes before symptoms appear, enabling earlier and potentially more effective treatment.
Clinical Studies
Freenome runs several significant clinical studies to validate its blood-based cancer detection tests. The PREEMPT CRC Study is the largest of its kind, with over 40,000 participants, validating colorectal cancer screening. The company also conducts the PROACT LUNG Study, designed for the early detection of lung cancer, with a target enrollment of up to 20,000 participants. Additionally, Freenome initiated the Vallania Study to develop tests for multiple cancer types, primarily targeting individuals aged 30 and above.
Partnerships and Collaborations
Freenome partners with biopharma companies for biomarker discovery, treatment monitoring, and predicting treatment response. The company collaborates with academic institutions and healthcare systems to advance early detection technology and integrate these tests into clinical care. These partnerships enhance Freenome's ability to bring its innovative cancer detection solutions to a broader audience.
Funding and Investment
Freenome has raised $254 million in new funding to accelerate its platform for early cancer detection. This investment supports the company’s research, clinical trials, and efforts to bring its multiomics technology platform to market. The funding underscores investor confidence in Freenome's approach to transforming early cancer detection.